Attached files

file filename
8-K - PDL BIOPHARMA, INC 8-K 12-15-2011 - PDL BIOPHARMA, INC.form8k.htm

Exhibit 99.1
 
    Graphic
 
Contacts:
 
John P. McLaughlin Jennifer Williams
PDL BioPharma, Inc. Cook Williams Communications, Inc.
775-832-8500  360-668-3701
John.McLaughlin@pdl.com jennifer@cwcomm.org
                                                                                                                                                                                    
PDL BioPharma Completes Regular Quarterly Dividend Payment

INCLINE VILLAGE, NV, December 15, 2011PDL BioPharma, Inc. (PDL) (NASDAQ: PDLI) today announced that it has paid the December 15, 2011, regular quarterly dividend payment of $0.15 per share to all stockholders owning shares of PDL as of December 8, 2011, the record date.

About PDL BioPharma
PDL pioneered the humanization of monoclonal antibodies and, by doing so, enabled the discovery of a new generation of targeted treatments for cancer and immunologic diseases. Today, PDL is focused on intellectual property asset management, investing in new royalty bearing assets and maximizing the value of its patent portfolio and related assets. For more information, please visit www.pdl.com.

NOTE: PDL BioPharma and the PDL BioPharma logo are considered trademarks of PDL BioPharma, Inc.

# # #